 |
Publisher: Peytchinski Publishing Ltd.
ISSN: 1312-773X (Online)
Issue: 2020, vol. 26, issue4
Subject Area: Dental Medicine
-
DOI: 10.5272/jimab.2020264.3348
Published online: 01 October 2020
Case report
J of IMAB. 2020 Oct-Dec;26(4):3348-3352
ZOLEDRONATE-ASSOCIATED RECURRENCE OF OSTEONECROSIS OF JAWS
Rosen Tsolov1
, Elena Firkova2, Georgi Yordanov3, Silvia Tsvetkova-Trichkova4,
1) Department of Maxillofacial and Oral surgery, Saint George Hospital University Medical Center, Plovdiv, Bulgaria.
2) Department of Periodontology and Oral Diseases, Faculty of Dental Medicine, Medical University – Plovdiv, Bulgaria.
3) Department of Oral Surgery, Faculty of Dental Medicine, Medical University – Plovdiv, Bulgaria.
4) Diagnostic Consulting Center, Saint George Hospital University Medical Center, Plovdiv, Bulgaria.
ABSTRACT:
Medication-related osteonecrosis of the jaws is a commonly reported complication in patients receiving antiresorptive medications. We report a case of bone necrosis followed by comparatively fast recurrence in a patient with intravenous administration of zoledronic acid. The purpose is to focus the attention of dental practitioners on the possibility of recurrence and the importance of regular check-ups since preventive measures today are one of the most important management strategies for patients treated with zoledronate.
Keywords: medication related osteonecrosis, zoledronate, recurrence,
- Download FULL TEXT /PDF 4507 KB/
Please cite this article as: Tsolov R, Firkova E, Yordanov G, Tsvetkova-Trichkova S. Zoledronate-associated recurrence of osteonecrosis of jaws. J of IMAB. 2020 Oct-Dec;26(4):3348-3352. DOI: 10.5272/jimab.2020264.3348
Correspondence to: Rosen Tsolov, Department of Maxillo-facial and Oral surgery, Saint George Hospital University Medical Center; 66, Peshtersko Shose blvd., Plovdiv, Bulgaria; E-mail: dr.rosentsolov@gmail.com
REFERENCES:
1. Ruggiero SL, Dodson TB, Fantasia J, Goodday R, Aqhaloo T, Mehrotra B, et al. American association of oral and maxillofacial surgeons position paper on medication-related osteonecrosis of the jaw - 2014 update. J Oral Maxillofac Surg.2014 Oct;72(10):1938-56. [PubMed]
2. Marx RE. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg. 2003 Sep;61(9):1115-7. [PubMed]
3. Landesberg R, Woo V, Cremers S, Cozin M, Marolt D, Vunjak-Novakovic G, et al. Potential pathophysiological mechanisms in osteonecrosis of the jaw. Ann N Y Acad Sci. 2011 Feb;1218:62-79. [PubMed]
4. Baron R, Ferrari S, Russell RG. Denosumab and bisphosphonates: different mechanisms of action and effects. Bone. 2011 Apr 1;48(4):677-92. [PubMed]
5. Cornish J, Bava U, Callon KE, Bai J, Naot D, Reid IR. Bone-bound bisphosphonate inhibits growth of adjacent non-bone cells. Bone. 2011 Oct;49(4):710-6. [PubMed]
6. Rogers MJ, Chilton KM, Coxon FP, Lawry J, Smith MO, Suri S. Bisphosphonates induce apoptosis in mouse macrophage-like cells in vitro by a nitric oxide-independent mechanism. J Bone Miner Res. 1996 Oct;11(10):1482-91. [PubMed]
7. Hoefert S, Schmitz I, Tannapfel A, Eufinger H. Importance of microcracks in etiology of bisphosphonate-related osteonecrosis of the jaw: a possible pathogenetic model of symptomatic and non-symptomatic osteonecrosis of the jaw based on scanning electron microscopy findings. Clin Oral Investig. 2010 Jun;14(3):271-84. [PubMed]
8. Pazianas M. Osteonecrosis of the jaw and the role of macrophages. J Natl Cancer Inst. 2011 Feb 2;103(3):232-40. [PubMed]
9. Reid IR, Bolland MJ, Grey AB. Is bisphosphonate-associated osteonecrosis of the jaw caused by soft tissue toxicity? Bone. 2007 Sep;41(3):318-320. [PubMed]
10. Lombard T, Neirinckx V, Rogister B, Gilon Y, Wislet S. Medication-related osteonecrosis of the Jaw: new insights into molecular mechanisms and cellular therapeutic approaches. Stem Cells Int. 2016; 2016:8768162. [PubMed]
11. Khan AA, Morrison A, Hanley DA, Felsenberg D, McCauley LK, O’Ryan F, et al. Diagnosis and management of osteonecrosis of trhe jaw: a systematic review and international consensus. J Bone Min Res.2015 Jan;30(1):3-23. [PubMed]
12. Landesberg R, Cozin M, Cremers S, Woo V, Kousteni S, Sinha S, et al. Inhibition of oral mucosal cell wound healing by bisphosphonates. J Oral MaxillofacSurg. 2008 May;66(5):839–847. [PubMed]
13. Vahtsevanos K, Kyrgidis A, Verrou E, Katodritou E, Triaridis S, Andreadis CG, et al. Longitudinal cohort study of risk factors in cancer patients of bisphosphonate-related osteonecrosis of the jaw. J Clin Oncol. 2009 Nov 10;27(32):5356-62. [PubMed]
14. Scoletta M, Arata V, Arduino PG, Arduino PG, Lerda E, Chiecchio A, et al. Tooth extractions in intravenous bisphosphonate-treated patients: a refined protocol. J Oral Maxillofac Surg. 2013 Jun;71(6):994-9. [PubMed]
15. Saad F, Brown JE, Van Poznak C, Ibrahim T, Stemmer SM, Stopeck AT, et al. Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases. Ann Oncol. 2012 May;23(5):1341-7. [PubMed]
16. Tsao C, Darby I, Ebeling PR, Walsh K, O’Brien-Simpson N, Reynolds E, et al. Oral health risk factors for bisphosphonate-associated jaw osteonecrosis. J Oral Maxillofac Surg. 2013 Aug;71(8):1360-6. [PubMed]
17. Otto S, Pautke C, Van den Wyngaert T, Niepel D, Schiodt M. Medication-related osteonecrosis of the jaw: prevention, diagnosis and management in patients with cancer and bone metastases. Cancer Treat Rev.2018 Sep;69:177-187. [PubMed]
18. Mong-Hun K, Dong-Keon L, Chang-Woo K, In-Seok S, Sang-Ho J. Clinical characteristics and recurrence-related factors of medication-related osteonecrosis of the jaw. J Korean Assoc Oral Maxillofac Surg. 2018 Oct;44(5):225-231. [PubMed]
19. Watters AL, Hansen HJ, Williams T, Chou JF, Riedel E, Halpern J, et al. Intravenous bisphosphonate-related osteonecrosis of the jaw: Long-term follow-up of 109 patients. Oral Surg Oral Med Oral Pathol Oral Radiol.2013 Feb;115(2):192–200. [PubMed].
Received: 30 August 2019
Published online: 01 October 2020